Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy

Simple item page
dc.citation.articleNumber90en_US
dc.citation.journalTitleThe AAPS Journalen_US
dc.citation.volumeNumber23en_US
dc.contributor.authorVarshney, Dhruven_US
dc.contributor.authorQiu, Sherry Yueen_US
dc.contributor.authorGraf, Tyler P.en_US
dc.contributor.authorMcHugh, Kevin J.en_US
dc.date.accessioned2021-07-30T16:36:53Zen_US
dc.date.available2021-07-30T16:36:53Zen_US
dc.date.issued2021en_US
dc.description.abstractToll-like receptors (TLRs) are a potential target for cancer immunotherapy due to their role in the activation of the innate immune system. More specifically, TLR7 and TLR8, two structurally similar pattern recognition receptors that trigger interferon and cytokine responses, have proven to be therapeutically relevant targets for cancer in numerous preclinical and clinical studies. When triggered by an agonist, such as imiquimod or resiquimod, the TLR7/8 activation pathway induces cellular and humoral immune responses that can kill cancer cells with high specificity. Unfortunately, TLR7/8 agonists also present a number of issues that must be overcome prior to broad clinical implementation, such as poor drug solubility and systemic toxic effects. To overcome the key limitations of TLR7/8 agonists as a cancer therapy, biomaterial-based drug delivery systems have been developed. These delivery devices are highly diverse in their design and include systems that can be directly administered to the tumor, passively accumulated in relevant cancerous and lymph tissues, triggered by environmental stimuli, or actively targeted to specific physiological areas and cellular populations. In addition to improved delivery systems, recent studies have also demonstrated the potential benefits of TLR7/8 agonist co-delivery with other types of therapies, particularly checkpoint inhibitors, cancer vaccines, and chemotherapeutics, which can yield impressive anti-cancer effects. In this review, we discuss recent advances in the development of TLR7/8 agonist delivery systems and provide perspective on promising future directions.en_US
dc.identifier.citationVarshney, Dhruv, Qiu, Sherry Yue, Graf, Tyler P., et al.. "Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy." <i>The AAPS Journal,</i> 23, (2021) Springer Nature: https://doi.org/10.1208/s12248-021-00620-x.en_US
dc.identifier.doihttps://doi.org/10.1208/s12248-021-00620-xen_US
dc.identifier.urihttps://hdl.handle.net/1911/111052en_US
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.rightsThis is an author's peer-reviewed final manuscript, as accepted by the publisher. The published article is copyrighted by Springer Nature.en_US
dc.titleEmploying Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapyen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpost-printen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Employing-Drug-Delivery-Strategies-to-Overcome-Challenges-using-TLR7-8-Agonists.pdf
Size:
284.5 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Faculty Publications
Bioengineering Publications